G1 Therapeutics to Participate in Four Investor Conferences in September 2020

Rhea-AI Summary

G1 Therapeutics (GTHX) has announced its participation in several investor conferences in September 2020. Key events include the Citi 15th Annual BioPharma Virtual Conference on September 10, the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 12:00 p.m. ET, and the Cantor Global Virtual Healthcare Conference on September 15 at 8:40 a.m. ET. Additionally, the Morgan Stanley 18th Annual Global Healthcare Conference will take place on September 16 at 4:15 p.m. ET. For live and archived presentations, visit G1's Events & Presentations page.

RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will participate in the following investor conferences in September 2020:

• Citi 15^th Annual BioPharma Virtual Conference: G1 will host investor meetings at the conference on Thursday, September 10, 2020.
• H.C. Wainwright 22^nd Annual Global Investment Conference: Chief Financial Officer Jennifer Moses will present a company update on Monday, September 14, 2020 at 12:00 p.m. ET.
• 2020 Cantor Global Virtual Healthcare Conference: Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company update on Tuesday, September 15, 2020 at 8:40 a.m. ET.
• Morgan Stanley 18^th Annual Global Healthcare Conference: Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company update on Wednesday, September 16, 2020 at 4:15 p.m. ET.

To access live and archived webcasts of the presentations, please visit the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
G1 Therapeutics, Inc.
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com

FAQ

What investor conferences will G1 Therapeutics participate in September 2020?

G1 Therapeutics will participate in four investor conferences: Citi BioPharma on September 10, H.C. Wainwright on September 14, Cantor Global Healthcare on September 15, and Morgan Stanley on September 16.

When is G1 Therapeutics presenting at the H.C. Wainwright Conference?

G1 Therapeutics will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 12:00 p.m. ET.

Who will present at the Cantor Global Virtual Healthcare Conference?

Mark Velleca, M.D., Ph.D., CEO of G1 Therapeutics, will present at the Cantor Global Virtual Healthcare Conference on September 15, 2020, at 8:40 a.m. ET.

What is the stock symbol for G1 Therapeutics?

The stock symbol for G1 Therapeutics is GTHX.

Where can I access G1 Therapeutics' conference presentations?

You can access live and archived webcasts of G1 Therapeutics' presentations on their Events & Presentations page on their website.